Focused on advancing the proprietary diagnostic technology, originally developed by Lilly, the collaboration agreement is part of Corgenix’ expanded contract services business unit for the healthcare and biotechnology industries.
Corgenix president and CEO Douglass Simpson said the collaboration strengthens the company’s program of strategic alliances in the fields of laboratory and research medicine.
"The Lilly collaboration in particular opens a new door for Corgenix as we continue to explore this technology in global clinical research as potential new technology to meet the needs of oncology clinicians worldwide," Simpson added.
Financial terms of the agreement remain undisclosed.